Dr. Lal PathLabs Q4 Results: Profit Rises 83%, Beats Estimates

Dr. Lal PathLabs Ltd.’s fourth quarter profit increased, beating analysts' estimates.

The diagnostic and healthcare testing services provider’s net profit rose 83% year-on-year to Rs 154.80 crore in the quarter ended March 31, 2025, according to its exchange filing. That compares with the Rs 99.5-crore consensus estimate of analysts tracked by Bloomberg.

• Revenue up 10.5% at Rs 602.60 crore versus Rs 545.40 crore (Bloomberg estimate: Rs 604.2 crore).

• Ebitda up 17% at Rs 169 crore versus Rs 144.70 crore (Bloomberg estimate: Rs 158.9 crore).

• Ebitda margin at 28% versus 26.5% (Bloomberg estimate: 26.3%).

• Net profit up 83% at Rs 154.80 crore versus Rs 84.50 crore (Bloomberg estimate: 99.5 crore).

Shares of Dr. Lal PathLabs were trading 0.36% higher, as compared with a 0.62% decline in the benchmark Nifty 50.

(This is a developing story).